Blog: Dean BestCould Nestle be weighing up major M&A move outside food?

Dean Best | 12 October 2017

Pfizer has this week announced it is reviewing the options it has for its consumer healthcare business. Might Nestle be interested?

The announcement from the US-based pharma giant has sparked talk among the equity analysts following Nestle that the world's largest food maker could be interested in buying an entity that includes Advil painkillers and Centrum vitamins.

In June, Nestle outlined where it plans to focus its resources on trying to drive growth and one of its strategies is to "pursue growth opportunities in consumer healthcare".

The statement came days after activist investor Third Point bought a stake in Nestle and called on the business to shake up its "staid culture".

However, the KitKat and Maggi owner insisted its management and board had earlier this year reviewed its "priorities", as well as the company's capital structure, to improve the group's ability to "deliver on its value creation model".

Could Nestle sell value in Pfizer's consumer healthcare arm?

Pfizer's consumer healthcare business generated revenues of US$3.41bn in 2016, a slight rise from the $3.4bn booked for 2015.

Sanford Bernstein food, home and personal care analyst Andrew Wood says Pfizer's consumer-health business is the fourth-largest in the sector, with "good market share in two of the biggest categories: vitamins and dietary Supplements and analgesics".

However, Wood believes Nestle may not make a move. "This will still be a big (Nestle's biggest ever), risky, ROIC-dilutive deal in a fairly new category. An analysis of Schneider's comments at [Nestle's] recent investor seminar suggests that this deal may be too far from Nestlé's core competencies of nutrition and skin. We cannot see Nestle operating in analgesics and cough and cold products…or buying Pfizer just to sell some significant parts/brands it does not want."

Alain Oberhuber, another analyst following Nestle who works for Swiss financial services firm MainFirst, suggests the company could be weighing up an approach but also argues a move may not materialise.

"We assume that some of these categories look interesting for Nestle, in particular the dietary supplement Centrum, calcium supplement Caltrate and the heal and wellness lifestyle brand Emergen-C and Chap Stick. These products would fit into Nestle’s health science as well as skin health," Oberhuber says. "However, the over-the-counter business does not fit into Nestle’s portfolio. Furthermore, the potential price of 4.5-5x revenues looks stretched and we remember CEO Mark Schneider who mentioned in one of statements that it is not the time for larger acquisitions."

Sectors: Mergers & acquisitions

Companies: Nestle

BLOG

What does Gen Z want from brands? IRI presents its view

Industry watchers IRI has published the findings of two studies in the US they claim can give an insight into the shopping patterns of those aged 21 and under - Gen Z....

NEWS

Spanish seafood firm Union Martin gets PE investment

Unión Martín, the Spain-based seafood supplier, has attracted investment from Alantra Private Equity....

BLOG

The identity of the buyer of Tyson's Kettle business emerges

In February, we reported Tyson Foods had sold its Kettle business, one of a series of non-protein disposals at the US meat giant. But the company would not disclose the buyer. This week, the new owner...

BLOG

Leading French grocers eye buying "alliance" - and suppliers aren't happy

Buying partnerships between France's food retailers have been a feature of the country's grocery landscape for a number of years but this week came news of a potentially significant new tie-up - and s...

BLOG

just-food off for Easter

A point of admin: just-food is closed tomorrow (Good Friday) and on Easter Monday. It promises to be a wet public holiday here in the UK but we'll likely console ourselves in chocolate....



Forgot your password?